Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/32462
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | |
dc.contributor.author | V, Carlos E. C. Abreu | |
dc.contributor.author | MORAES, Fabio Y. | |
dc.contributor.author | MIRANDA, Fabiana A. | |
dc.contributor.author | SIQUEIRA, Gabriela S. M. | |
dc.contributor.author | GADIA, Rafael | |
dc.contributor.author | HADDAD, Cecilia K. | |
dc.contributor.author | CARVALHO, Heloisa A. | |
dc.date.accessioned | 2019-06-26T17:29:01Z | - |
dc.date.available | 2019-06-26T17:29:01Z | - |
dc.date.issued | 2018 | |
dc.identifier.citation | JOURNAL OF GLOBAL ONCOLOGY, v.4, 2018 | |
dc.identifier.issn | 2378-9506 | |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/32462 | - |
dc.description.abstract | Purpose Stereotactic body radiation therapy (SBRT) has emerged as a treatment option for patients with non-small-cell lung cancer (NSCLC). We report the clinical outcomes and toxicity for patients with inoperable primary NSCLC treated with SBRT. Methods Between 2007 and 2015, 102 consecutive lung lesions were treated with SBRT at our center, of which 59 primary NSCLC lesions (from 54 patients with inoperable disease) were retrospectively reviewed (43 lesions were excluded because of metastases or because there was no biopsy specimen). We report infield local control (LC) per SBRT target, regional or distant failure-free survival, and overall survival (OS) per patient, using Kaplan-Meier estimates. Serious toxicity was retrospectively scored using Common Terminology Criteria for Adverse Events, version 4. Results Most of the 54 patients were men (n = 41; 76%), median age was 75 years; stage IA (n = 36; 66%) and adenocarcinoma (n = 43; 80%) were the most common stage and histologic diagnosis, respectively. Five patients had two lung lesions. A median of three fractions (range, 3 to 5 fractions) and a total median dose of 54 Gy (range, 45 to 60 Gy) per lesion were prescribed. The median follow-up was 17.8 months (range, 4 to 56.4 months). The 2-year rates of LC, regional or distant failure-free survival, and OS were 89.1% (95% CI, 72.2% to 96%), 79% (95% CI, 59.8% to 89.8%), and 80% (95% CI, 64% to 89.8%), respectively. Grade 3 to 4 toxicities were observed in two patients (3%): grade 3 pneumonitis (n = 1) and grade 4 skin toxicity (n = 1). Conclusion SBRT results in high rates of 2-year LC, regional or distant failure-free survival, and OS with low rates of severe toxicity in patients with inoperable primary NSCLC disease. (C) 2018 by American Society of Clinical Oncology | eng |
dc.language.iso | eng | |
dc.publisher | AMER SOC CLINICAL ONCOLOGY | eng |
dc.relation.ispartof | Journal of Global Oncology | |
dc.rights | openAccess | eng |
dc.subject.other | hypofractionated radiotherapy | eng |
dc.subject.other | ablative radiotherapy | eng |
dc.subject.other | survival | eng |
dc.subject.other | toxicity | eng |
dc.subject.other | outcomes | eng |
dc.subject.other | tumors | eng |
dc.title | Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non-Small-Cell Lung Cancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution | eng |
dc.type | article | eng |
dc.rights.holder | Copyright AMER SOC CLINICAL ONCOLOGY | eng |
dc.identifier.doi | 10.1200/JGO.18.00020 | |
dc.identifier.pmid | 30085881 | |
dc.subject.wos | Oncology | eng |
dc.type.category | original article | eng |
dc.type.version | publishedVersion | eng |
hcfmusp.author.external | V, Carlos E. C. Abreu:Hosp Sfrio Libanes, Sao Paulo, SP, Brazil | |
hcfmusp.author.external | MORAES, Fabio Y.:Hosp Sfrio Libanes, Sao Paulo, SP, Brazil; Univ Toronto, Toronto, ON, Canada; Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada | |
hcfmusp.author.external | MIRANDA, Fabiana A.:Hosp Sfrio Libanes, Sao Paulo, SP, Brazil | |
hcfmusp.author.external | SIQUEIRA, Gabriela S. M.:Hosp Sfrio Libanes, Sao Paulo, SP, Brazil | |
hcfmusp.author.external | GADIA, Rafael:Hosp Sfrio Libanes, Sao Paulo, SP, Brazil | |
hcfmusp.author.external | HADDAD, Cecilia K.:Hosp Sfrio Libanes, Sao Paulo, SP, Brazil | |
hcfmusp.description.volume | 4 | |
hcfmusp.origem | WOS | |
hcfmusp.origem.id | WOS:000462457700001 | |
hcfmusp.origem.id | 2-s2.0-85060558783 | |
hcfmusp.publisher.city | ALEXANDRIA | eng |
hcfmusp.publisher.country | USA | eng |
hcfmusp.relation.reference | Bezjak A, 2016, INT J RADIAT ONCOL, V96, pS8, DOI 10.1016/j.ijrobp.2016.06.035 | eng |
hcfmusp.relation.reference | Abreu CECV, 2015, J BRAS PNEUMOL, V41, P376, DOI 10.1590/S1806-37132015000000034 | eng |
hcfmusp.relation.reference | de Moraes FY, 2016, CLINICS, V71, P101, DOI 10.6061/clinics/2016(02)09 | eng |
hcfmusp.relation.reference | Fakiris AJ, 2009, INT J RADIAT ONCOL, V75, P677, DOI 10.1016/j.ijrobp.2008.11.042 | eng |
hcfmusp.relation.reference | Kelly P, 2010, INT J RADIAT ONCOL, V78, P1387, DOI 10.1016/j.ijrobp.2009.09.070 | eng |
hcfmusp.relation.reference | Koshy M, 2015, INT J RADIAT ONCOL, V91, P344, DOI 10.1016/j.ijrobp.2014.10.002 | eng |
hcfmusp.relation.reference | Lackey A, 2013, SEMIN INTERVENT RAD, V30, P133, DOI 10.1055/s-0033-1342954 | eng |
hcfmusp.relation.reference | Nagata Y, 2005, INT J RADIAT ONCOL, V63, P1427, DOI 10.1016/j.ijrobp.2005.05.034 | eng |
hcfmusp.relation.reference | Nanda RH, 2015, CANCER-AM CANCER SOC, V121, P4222, DOI 10.1002/cncr.29640 | eng |
hcfmusp.relation.reference | Naruke T, 2001, ANN THORAC SURG, V71, P1759, DOI 10.1016/S0003-4975(00)02609-6 | eng |
hcfmusp.relation.reference | Nyman J, 2006, LUNG CANCER-J IASLC, V51, P97, DOI 10.1016/j.lungcan.2005.08.011 | eng |
hcfmusp.relation.reference | Onishi H, 2007, J THORAC ONCOL, V2, pS94, DOI 10.1097/JTO.0b013e318074de34 | eng |
hcfmusp.relation.reference | Potters L, 2010, INT J RADIAT ONCOL, V76, P326, DOI 10.1016/j.ijrobp.2009.09.042 | eng |
hcfmusp.relation.reference | Senthi S, 2013, RADIOTHER ONCOL, V106, P276, DOI 10.1016/j.radonc.2013.01.004 | eng |
hcfmusp.relation.reference | Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387 | eng |
hcfmusp.relation.reference | Sobin LH, 2011, TNM CLASSIFICATION M | eng |
hcfmusp.relation.reference | Sun B, 2017, CANCER-AM CANCER SOC, V123, P3031, DOI 10.1002/cncr.30693 | eng |
hcfmusp.relation.reference | Timmerman R, 2006, J CLIN ONCOL, V24, P4833, DOI 10.1200/JCO.2006.07.5937 | eng |
hcfmusp.relation.reference | Timmerman R, 2010, JAMA-J AM MED ASSOC, V303, P1070, DOI 10.1001/jama.2010.261 | eng |
hcfmusp.relation.reference | U. S. Department of Health and Human Services, 2010, COMMON TERMINOLOGY C | eng |
hcfmusp.relation.reference | Ueki N, 2015, J THORAC ONCOL, V10, P116, DOI 10.1097/JTO.0000000000000359 | eng |
hcfmusp.relation.reference | Uematsu M, 2001, INT J RADIAT ONCOL, V51, P666, DOI 10.1016/S0360-3016(01)01703-5 | eng |
hcfmusp.relation.reference | Zhang J, 2011, INT J RADIAT ONCOL, V81, pE305, DOI 10.1016/j.ijrobp.2011.04.034 | eng |
hcfmusp.relation.reference | Zimmermann FB, 2006, ACTA ONCOL, V45, P796, DOI 10.1080/02841860600913210 | eng |
dc.description.index | MEDLINE | eng |
hcfmusp.citation.scopus | 3 | - |
hcfmusp.scopus.lastupdate | 2024-03-29 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MDR Artigos e Materiais de Revistas Científicas - HC/InRad Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_V_Stereotactic_Body_Radiation_Therapy_for_BiopsyProven_Primary_NonSmallCell_2018.PDF | publishedVersion (English) | 768.74 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.